Minerva Neurosciences (NERV) is now covered by Citizens Jmp. They set an "outperform" rating and a $14.00 price target on the stock.
Minerva Announces Leadership Transition [Yahoo! Finance]
Minerva Announces Leadership Transition
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia [Seeking Alpha]